Ridaforolimus demonstrated its ability to cross the blood–brain barrier and inhibit mTOR activity, as evidenced by a decrease in its downstream effectors in tumor specimens; pS6 levels were reduced, and phosphorylated 4E-BP1(p4E-BP1) was reduced by >80% compared to patient serum baseline [81]. Here, MTOR is linked to neoplasm.